What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
For many adults with newly diagnosed glioblastoma, treatment starts with surgery if the tumor can be removed safely, followed by radiation given with temozolomide chemotherapy and then additional temozolomide. The sequence is not right for everyone: tumor location, health, tumor findings, functional status, and personal priorities all shape the plan. A neuro-oncology team can explain which options fit an individual case.
What treatment usually involves
The National Cancer Institute (NCI) describes the usual initial approach for adults with newly diagnosed glioblastoma as surgery, when feasible, followed by radiation with daily temozolomide and then six cycles of temozolomide alone. This is a common treatment sequence, not a rule that every patient can or should follow.
- Surgery or biopsy: The team obtains tumor tissue and, when it is safe, removes as much tumor as possible without unacceptable risk to neurological function.
- Radiation with temozolomide: After surgery and recovery, external-beam radiation is given alongside daily temozolomide for the concurrent-treatment phase.
- Maintenance temozolomide: Temozolomide is then given in additional cycles. NCI describes six cycles in its standard newly diagnosed approach.
U.S. temozolomide labeling also identifies use for adults with newly diagnosed glioblastoma in combination with radiotherapy and then as maintenance treatment; the DailyMed labeling search result says it was revised in January 2025. The patient’s treating team determines whether that regimen and schedule are suitable.
Recommended Free Tools
Will surgery be needed?
When tumor removal may be possible
Surgery can reduce the amount of tumor and provide tissue needed to confirm the diagnosis and assess molecular features. When feasible, clinicians generally aim to remove as much as can be safely removed. The priority is not removal at any cost: the tumor’s location, the person’s health, and the potential effect on speech, movement, cognition, or other neurological function all matter.
#1 Best Overall
When biopsy may be chosen
If removing tumor would carry too much risk, a biopsy may be used to obtain tissue for diagnosis and testing. The choice between resection and biopsy is individualized. Comparisons of outcomes between people who had resection and those who had biopsy are observational, and differences in who was selected for each procedure can affect the apparent results. They do not establish that a particular operation will improve one person’s outcome.
What do radiation and temozolomide do?
Radiation is a local treatment directed at the tumor area. Temozolomide is an oral chemotherapy drug used as a systemic treatment. In the NCI-described randomized study of newly diagnosed glioblastoma, the group that received radiation with concurrent and subsequent temozolomide had a 3-year overall survival rate of 16.0%, compared with 4.4% in the radiation-alone group. These are results for groups in that study, not an individual’s forecast; the accessed NCI account does not state the study year.
The combined regimen has randomized-trial evidence in initial treatment, but its suitability still depends on the clinical situation. The treating team can explain the proposed schedule, monitoring, likely burdens, and how the expected benefits compare with the patient’s priorities.
What does MGMT promoter methylation mean?
MGMT promoter methylation is a tumor finding relevant to prognosis and to discussion of temozolomide. NCI describes it as a favorable prognostic factor, while noting that evidence for using it to predict an individual’s response to temozolomide is less certain. A result does not guarantee that the drug will work or show that it cannot work.
In one molecular-subset study described by NCI, median overall survival was 18.2 months for patients whose tumors had MGMT promoter methylation and 12.2 months for those whose tumors did not. The accessed NCI account does not provide a publication year for these figures. They are historical study-group results, not expected survival times for a particular person.
Are tumor treating fields an option?
Tumor treating fields are delivered using a clinician-directed device. FDA records describe Optune use with temozolomide for a defined U.S. population of adults with newly diagnosed supratentorial glioblastoma after maximal debulking surgery and completion of radiation with concomitant standard chemotherapy; FDA records also describe a recurrent-disease indication. These indications do not mean the device is appropriate for every patient.
Rank #4
Guidance differs by jurisdiction. In the UK, NICE advises against offering tumor treating fields as part of management for newly diagnosed grade 4 glioma. FDA authorization and NICE guidance answer different questions within different health systems, so patients should ask their team what applies where they receive care and why.
What changes if glioblastoma recurs?
There is no single established treatment sequence for recurrence. Depending on the tumor, prior treatment, health, and goals, options may include a clinical trial, repeat surgery for selected patients, re-irradiation in selected circumstances, or systemic therapy. NCI notes that evidence for many recurrence approaches is limited, often coming from noncontrolled studies and case series; patient selection can affect reported outcomes.
Best Value
A clinical trial may be worth discussing, but participation does not guarantee access to an effective treatment. NCI’s patient information directs readers to its trial search as an information resource, not as formal treatment guidance. A neuro-oncology team can help assess eligibility and explain what a trial involves alongside other available options.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What should patients ask their neuro-oncology team?
- What is the goal of each proposed step, and why is this sequence appropriate for this tumor and this person’s health?
- Is tumor removal considered safe, or is biopsy a better way to obtain the needed tissue?
- What do the pathology and molecular results—including MGMT promoter methylation—mean for treatment discussions?
- What schedule, monitoring, practical demands, and quality-of-life trade-offs should we expect from radiation, temozolomide, or device therapy?
- If the disease recurs, what options might be considered, and what evidence supports each one?
- Are there clinical trials for which the patient may be eligible, and how would participation compare with other options?
The NCI patient PDQ is intended to inform patients and caregivers; it explicitly says it does not provide formal guidelines or recommendations for making health-care decisions. Individual treatment decisions belong in discussion with the treating team.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →
